Takeda Makes Organizational and Reporting Line Changes

By Pharma News - DCAT Publisher

March 17, 2014

Takeda Pharmaceutical Company Limited has made organizational and reporting line changes in line with Christophe Weber's assumption as Takeda's chief operating officer (COO) as of April 1, 2014, which the company had previously announced. Upon this date, Weber will be responsible for all operational activities and report to Yasuchika Hasegawa as Takeda's president and CEO. Specifically, all functions and divisions currently reporting to the president and CEO will report directly to Weber as COO. These steps are designed to create a global operating structure and achieve performance that meets the global standards, according to the company.

Furthermore, Takeda's commercial operations outside Japan and the Vaccine Business Division will report directly to the COO. Weber has experience in commercial operations across a variety of geographies and pharmaceutical product areas, including vaccines. This elevation of the reporting line to the COO is an indication of the importance Takeda places on its global commercial operations, according to the company. In addition, the Office of the President and CEO will be integrated into the Corporate Strategy Department to provide strategic and operational support.

Source:
Takeda